key: cord-0855923-3o8ski4e authors: nan title: Community‐acquired respiratory viruses date: 2004-10-25 journal: Am J Transplant DOI: 10.1111/j.1600-6135.2004.00734.x sha: ec6c460d1e77fcc1ebe0d3b07a8061d33c41c65b doc_id: 855923 cord_uid: 3o8ski4e nan While a number of different species of viruses cause upper and lower respiratory infections in transplant recipients, some similarities exist between these pathogens. In general, transmission of all of these viral pathogens occurs by spread from person to person through direct or close contact with contaminated secretions which may involve droplets or fomites. In addition, influenza virus may be spread by small particle aerosols. Accordingly, attention to good hygienic practices, in particular hand washing, should be part of infection control and prevention both in and out of the hospital. Supportive care is a mainstay of treatment. Specific antiviral agents are not available for coronavirus and parainfluenza. Specific data on RSV, influenza and PIV in the transplant population are discussed in more detail. The RNA virus is a cause of seasonal annual epidemics worldwide. In temperate climates RSV strikes in the fall, winter and early spring. By 2 years of age, virtually all children have experienced a primary infection. In recent years it is has become clear that re-infection can occur throughout life. While symptoms of RSV infection tend to be milder in older children and adults, these individuals may serve as a reservoir for transmission to more susceptible hosts. RSV has been recognized as a cause of severe disease after bone marrow transplantation (BMT) (1) (2) (3) (4) . Likewise, it is recognized as a cause of respiratory disease after pediatric solid-organ transplantation and is being increasingly recognized in adult recipients (3, (5) (6) (7) (8) (9) . Risk-factors for development of lower respiratory tract disease in BMT recipients with RSV. infection include lymphocytopenia and neutropenia (4) . As many as 60% of BMT recipients infected with RSV will develop lower respiratory tract disease. Once lower tract disease is present, mortality rates ranging from 30 to 80% have been reported (1, 4, 7, 10) . Risk factors for more severe disease after organ transplantation include infection in children under a year of age or with underlying lung disease (5) (6) (7) (8) (9) . Early acquisition of RSV after transplantation or after augmented immunosuppression has been associated with increased severity of disease in some but not all studies (3, (5) (6) (7) (8) (9) (11) (12) (13) . Definitive diagnosis is made by growth of RSV in cell lines such as HeP-2. However, the virus is quite labile and sensitivity diminishes quickly if specimens are not inoculated promptly onto cell culture lines. A number of commercial rapid antigen detection kits and shell vial assays are available that permit the diagnosis to made quickly and with increased sensitivity compared to culture in children (14) . However, adults (including immunocompromised patients) may have low titers of virus in the upper respiratory tract so that the sensitivity of antigen detection in adults is lower than seen for children. Polymerase chain reaction assays (PCR) are also available in some laboratories and one commercial multiplex assay (Hexaplex, Podesse, Inc; Waukesha, WI, USA.) is approved by the Food and Drug Administration (FDA). Nasal washes or aspirates have been shown to be superior to nasal swab specimens for the diagnosis of RSV. Bronchoalveolar lavage is recommended for assessment in adults with suspected lower respiratory tract disease. A review of the diagnosis of RSV is provided in Table 1 . Supportive care is recommended (BIII). The role of specific antiviral treatment is controversial. Ribavirin has been shown to have in vitro activity against RSV and the aerosolized form of this drug has been approved for the treatment of lower respiratory tract disease due to RSV in certain at-risk populations. Despite its FDA approval, convincing data describing the clinical efficacy of this agent are lacking and a consensus on the utility of this drug in the treatment of RSV disease does not currently exist. Published data on the treatment of RSV disease in solid organ transplant recipients is very limited. However experience from the treatment of BMT recipients may provide guidance for the treatment of RSV disease in solid organ transplant recipients. BMT recipients have a high mortality rate from RSV pneumonia even with the use of aerosolized ribavirin (1-3,7,10,11) prompting the clinical investigation of additional therapeutic options in this patient population. A noncontrolled study using a combination of ribavirin with IVIG with higher RSV titers (RSV-IVIG, Respigam) was performed which appeared to demonstrate a benefit when used early after symptoms developed in BMT recipients (15, 16) . The high mortality rate in this patient population would lead many to recommend early therapy (BII). Combinations of aerosolized ribavirin and RSV IVIG (15, 16) or palivizumab (17) (Synagis, MedImmune, Inc; Gaithesburg, Maryland.), an RSV-specific monoclonal antibody, appear to be beneficial in some BMT recipients even when they present with lower respiratory tract disease. Based on these experiences, many experts would recommend the use of the combination of aerosolized ribavirin and either RSV IVIG or palivizumab for the treatment of RSV upper respiratory tract or lower respiratory tract infection in BMT recipients (BII). Combining this experience with the limited published experience of treatment of RSV disease in solid organ transplant recipients provides support for the following recommendations (Table 1) . Aerosolized ribavirin use in the treatment of some solid organ transplant patients with lower tract disease has been reported with seeming benefit (7,13) (BIII). However, these studies report retrospective experiences. Based upon published experience from pediatric organ transplant recipients, patients without risk factors for severe disease and with only upper respiratory infections are unlikely to benefit from aerosolized ribavirin (DII). For patients with upper respiratory tract disease and the presence of risk factors, and for those organ transplant recipients with lower respiratory tract disease the use of aerosolized ribavirin in combination with RSV IVIG or pavilizumab should be considered (BIII). Prophylaxis with the RSV-specific monoclonal antibody (Palivizumab) or high titer RSV-IVIG has been shown to be effective for specific groups of high-risk infants and young children (18) (A1). However, no studies have been conducted to evaluate their use in the solid organ transplant setting and the cost of the weight adjusted dosing of these products in adults would be extremely high. The unexpected increased risk of death in children with cyanotic heart disease who received RSV IVIG shows the inability to generalize the use of this immunoprophylaxis from one population to another without study. Despite this, some experts would support the use of immunoprophylaxis for Studies are necessary to define risk factors for severe disease in adult solid-organ transplant recipients and to develop more sensitive rapid diagnostic assays for use in adults. The utility of immunoproprophylaxis in recipients of transplantation also requires evaluation. Finally, trials are also needed to confirm the utility of aerosolized ribavirin, alone or in combination with RSV-IVIG in the treatment of patients at risk of progressing to or who present with lower respiratory tract disease. Influenza virus, an orthomyxovirus, is considered one of the most important community-acquired viruses leading to substantial morbidity and mortality worldwide. Antigenic variability gives this virus a survival advantage allowing for its continued virulence during yearly epidemics. Few studies have examined the prevalence of influenza virus infection prospectively in organ transplant recipients (12) . Retrospective studies demonstrate the potential for substantial disease in pediatric recipients after influenza infection (20, 21) . Reviews of influenza virus infection after adult organ transplantation document variable levels of severity (6,12,22-24) which may be due to different levels of immunosuppression, type of transplantation, and seasonal variation of influenza virulence. In addition, differences in prevention through vaccination policies or disparate response rate to vaccination of patients of different ages or under different immunosuppressive regimens undoubtedly affect the disease severity (25) . Diagnosis of influenza infection is proven by isolation of the virus in culture. Other rapid methods, such as shell vial culture, antigen detection, or detection of neuraminidase activity are relatively sensitive and specific, depending on the specimen and patient source, and are commercially available. Some of these rapid tests can be used for officebased diagnostic testing. Adequate specimen collection and timing of sampling also play important roles in identifying pathogens. When viral cultures are performed, specimens should be obtained during the first few days of illness to maximize yield as viral load may decrease rapidly there afterwards. Cultures typically turn positive within 2-6 days. Rapid diagnostic tests for identification of influenza A and B antigens are commercially available. A nasopha-ryngeal aspirate specimen is considered optimal. Use of throat swabs or nasopharyngeal swab has tended to result in lower levels of sensitivity. A review of the diagnosis of influenza is provided in Table 1 . Prompt treatment of influenza A infection with amantadine, rimantadine, or the newer neuraminidase inhibitors, zanamivir and oseltamivir has been effective in studies on healthy adults. Only the latter two drugs have efficacy against influenza B; early treatment of influenza with inhaled zanamivir or oral oseltamivir appears to reduce the likelihood of lower respiratory tract complications (e.g. bronchiolitis, pneumonia) but none of the drugs has been proven to be efficacious in preventing serious complications from influenza (26) . Retrospective analysis indicates that early antiviral treatment with amantadine or rimantadine reduces the likelihood of developing pneumonia in patients with acute leukemia or who have undergone BMT. A review of recommendations for the treatment of influenza virus infections in solid organ transplant recipients is provided in Table 1 . Despite the absence of data in organ transplant recipients, most transplant physicians would recommend the use of an antiviral agent for the treatment of organ transplant recipients with influenza virus infections (BIII); many experts would consider the use of a neuraminidase inhibitor either alone or in combination with another drug because of the concern of acquisition of resistance associated with the use of amantadine or rimantadine which may exceed a rate of 30% in these patients. Finally, ribavirin also has in vitro activity against influenza virus and anecdotal reports of its use in immunocompetent hosts with severe influenza infections suggested possible activity (27) . Accordingly some would advocate the addition of aerosolized ribavirin to one of the antiviral agents for a transplant patient with serious influenza infection (CIII). The use of influenza vaccine in high-risk individuals (including transplant recipients) >6 months of age is strongly recommended (BII). Influenza vaccine should also be administered to people who have contact with high-risk patients such as health care workers and household contacts (BIII). The response to influenza vaccine has been studied in a number of transplant settings (25) . While the vaccine year, specific influenza strain, and recipient type lead to variations in antibody response, several conclusions can be made. First, transplant recipients do not have as strong a response to vaccine as healthy controls. Despite this, 30-100% of patients achieved protective hemagglutinationinhibiting serum antibody titers. Accordingly, yearly vaccination should be strongly considered (AII). Yearly vaccination should likewise be recommended for all health care workers and household contacts. Chemoprophylaxis with antiviral agents can be used effectively in at-risk populations who have not received vaccine or who have not had an opportunity to respond to recent vaccination during the time when influenza is already circulating in the community (BIII). However, failure of amantadine or rimantadine may occur on the basis of antiviral resistance in communities where prophylactic or therapeutic use of these agents is high. The diagnosis of parainfluenza relies on viral isolation, shell vial assays or the use of rapid antigen detection using fluorescent antibody staining techniques directly on specimen or the cultured cells. In addition, RNA detection techniques have recently become available. Prolonged viral shedding can occur in immunosuppressed hosts. An overview of the diagnosis of parainfluenza virus is provided in Table 1 . Specific antiviral treatment is not available for PIV infection but ribavirin has in vitro activity and has been used to treat lung transplant recipients with lower tract disease (8) . Because no other therapeutic options are currently available, consideration can be given to the use of aerosolized ribavirin for high-risk patients with PIV-associated severe lower tract disease (CIII) ( Table 1) . However, analysis of uncontrolled studies of aerosolized ribavirin in BMT recipients with parainfluenza virus disease found little evidence of for antiviral effects or clinical benefit (11) . Similarly, the early use of oral ribavirin was of little benefit in preventing the progression from asymptomatic or mild upper respiratory tract symptoms to lower respiratory tract disease. No specific prophylaxis is available for PIV. As noted above, good attention to infection control practices is necessary to prevent nosocomial transmission (19) . Outside the hospital setting infection control methods can be challenging. Educating recipients and their families about the risk of community-acquired viruses and methods of their spread will allow them to avoid some exposures. Studies defining the potential therapeutic role of ribavirin in the treatment of PIV disease are necessary. In addition, multicentered-studies aimed at identifying the potential prophylactic benefit of polyclonal IVIG (containing antibodies against PIV and other respiratory viruses) would also be of benefit. An outbreak of respiratory syncytial virus in a bone marrow transplant center Community respiratory virus infections in immunocompromised patients with cancer Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients Respiratory syncytial virus infections in pediatric liver transplant recipients Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Community respiratory viruses: organ transplant recipients Community-acquired respiratory viruses after hemopoietic stem cell or solid organ transplantation Paramyxovirus infection in lung transplant recipients Community respiratory viral infection in adult lung transplant recipients Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience Respiratory viruses in adult liver transplant recipients Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin Respiratory syncytial virus: a comparison of diagnostic modalities Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation -a compassionate use experience Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group Infection control of nosocomial respiratory viral disease in the immunocompromised host Influenza B virus infection in pediatric solid organ transplant recipients Parainfluenza and influenza virus infections in pediatric organ transplant recipients Influenza A in immunocompromised patients Prevention and treatment of influenza in immunocompromised patients Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: a case report and review of the literature Immunization of pediatric solid organ transplant candidates and recipients Ribavirin aerosol treatment of influenza